Vertigo Class Research Articles

Hearing Outcomes Following Endolymphatic Duct Blockage Surgery and Factors Associated with Improved Audition at Two Years Follow-Up.

Objective: To evaluate hearing outcomes at 2 years post endolymphatic duct blockage (EDB) surgery, with an analysis of factors that may predict hearing improvement. Study Design: Retrospective comparative study. Setting: Tertiary care center. Subjects: Definite Ménière's Disease (MD) patients undergoing EDB for refractory disease. Methods: Chart review was conducted to assign cases to one of the three hearing outcome groups (deteriorated, stable, and improved). All cases that met our inclusion criteria were selected. Preoperative data collected were audiograms, bithermal caloric tests, preoperative vertigo episodes, history of previous ear surgery for Ménière, intratympanic steroid injections (ITS) and intraoperative endolymphatic sac (ELS) tear or opening. Postoperative data collected at 24 months were audiograms, vertigo episodes and bithermal caloric testing. Results: Preoperative vertigo episodes, caloric paresis and history of surgery, ITS injections or ELS integrity, as well as postoperative vertigo class distribution and caloric paresis changes were not different between our groups. Preoperative word recognition score (WRS) was lowest in the improved hearing group (p = 0.032). The persistence of tinnitus at 2 years postoperatively was associated with deteriorated hearing (p = 0.033). Conclusions: There are no strong predictors of hearing improvement on presentation pre-EDB, but low preoperative WRS may be the best estimator available. Therefore, ablative interventions should be considered very carefully in patients presenting with low WRS, as they may benefit more from EDB; there is a fair chance of a good hearing outcome with EDB surgery. Persistence of tinnitus can reflect deteriorating audition. Vertigo control and hearing preservation are independent outcomes of EDB surgery, making it desirable as an early intervention for refractory MD cases.

A Comparison of Endolymphatic Sac Decompression and Intratympanic Gentamicin for Treatment of Meniere’s Disease

Background and Objectives Meniere’s disease (MD) is primarily managed by lifestyle and dietary changes. There are several non-medical treatment options for medically intractable MD; however, treatment results still remain controversial. This study aims to review the treatment outcome of endolymphatic sac decompression (ESD) and intratympanic gentamicin (ITG) for MD refractory to medical management.Subjects and Method The medical records of 50 patients, diagnosed with definite MD intractable to medical management, who underwent ESD or ITG from 2010 to 2020 at a tertiary referral hospital, were retrospectively reviewed. ESD was first considered in patients with serviceable hearing (pure tone audiometry average value less than 50 dB, speech discrimination score of 50% or greater). One-year post-treatment audiological changes and vertigo control were reviewed and compared between the two groups.Results Fifty patients (ears) were enrolled in this study (ESD, n=27; ITG, n=23). There was a post-treatment hearing gain (2.3 dB HL) in the ESD group (p=0.509), while there was an overall post-treatment hearing decline (2.2 dB HL) in the ITG group (p=0.178), with no significant difference between two groups regarding hearing change (p=0.212). Regarding vertigo control, 66.6% and 56.5% patients in the ESD and ITG groups, respectively, were classified as vertigo class A or B, with statistically significant difference between both groups (p=0.027).Conclusion ESD conferred better post-treatment vertigo control than ITG, but there were no significant hearing changes in both groups. ESD is an effective treatment for patients with medically intractable MD who has serviceable hearing.

Treatment of Meniere’s disease with intratympanic dexamethazone plus high dosage of betahistine

PurposeThe aim of the present study was to assess if the combined therapy of intratympanic dexamethasone (ITD) and high dosage of betahistine (HDBH) is able to provide increased vertigo control compared to ITD alone in patients suffering from definite unilateral Meniere’s disease (MD). Materials and methodsConsecutive MD patients were enrolled and randomly divided in two groups, each comprising 33 cases. Group A received a combination of ITD and identical-appearing placebo pills while Group B received a combination of ITD and HDBH. ITD protocol consisted of three consecutive daily injections. HDBH comprised 144mg/day (48mg tid). The main outcome measures were: 1) vertigo class, pure tone average (PTA), speech discrimination score (SDS) and Functional Level Score (FLS) according to the American Academy of Otolaryngology-Head and Neck Surgery criteria; 2) complete and substantial vertigo control according to the Kaplan–Meier survival method. ResultsSixty two patients completed the 24-month follow-up. A complete vertigo control was achieved in 14 patients (44%) from Group A and in 22 patients (73.3%) from Group B, statistically significant (p=0.01). Complete vertigo relief is also significant according to the Kaplan–Meier method: p=0.027, log rank test. Substantial vertigo control was obtained in 21 patients (65.6%) in Group A and 27 patients (90%) in Group B. The difference is statistically significant, p=0.02. The difference is significant according to the Kaplan–Meier method: p=0.035, log rank test. No significant differences between hearing levels and tinnitus scores were demonstrated between the groups. ConclusionsOur preliminary results demonstrate that complete and substantial vertigo control is significantly higher in patients treated with a combination of HDBH and ITD.

Middle fossa vestibular neurectomy for refractory vertigo: less is more.

This study aimed to evaluate outcomes of the middle fossa (MF) superior vestibular neurectomy in unilateral Ménière's disease. Case series with preoperative and postoperative analysis of the 1995 American Academy of Otolaryngology hearing stage and vertigo class, gait instability, and results of vestibular-evoked myogenic potentials (VEMP). Four out of the 5 patients had total vertigo control (class A) and 1 had near total control (class B) by the last visit (mean follow-up, 23.6 months). There were no changes in hearing thresholds and hearing stage. Four patients had resolution of their gait instability by 2 months after surgery. Postoperative VEMP responses were preserved in all 3 patients with positive VEMP preoperatively. This is the first report of the anatomical and functional preservation of the inferior vestibular nerve in vestibular neurectomy for the treatment of refractory vertigo in unilateral Ménière's disease, with VEMP testing before and after vestibular neurectomy. The modified technique limits the surgical dissection and may help avoid complications such as postoperative hearing loss and persistent gait instability. This approach is indicated when other more conservative measures have failed, and patient selection is paramount to avoid long-term complications.

Endolymphatic Sac Surgery Versus Intratympanic Gentamicin for the Treatment of Intractable Ménière’s Disease

1) To review a 10-year experience of endolymphatic sac surgery (ESS) and intratympanic gentamicin (ITG) for intractable Ménière's disease (MD), and 2) to compare preoperative and postoperative outcomes. Retrospective chart review and survey. Tertiary care center. Patients treated with ESS or ITG between 1997 and 2007 at London Health Sciences Centre were eligible for recruitment. ESS or ITG. 1) 1995 American Academy of Otolaryngology-Head and Neck Surgery hearing stage, vertigo class, and functional level; and 2) a 40-item validated quality-of-life questionnaire (MD Outcome Questionnaire). Chi-squared and t tests. Sixty-seven patients were recruited (n = 30 ESS; n = 37 ITG). Preoperatively, the ITG group had poorer hearing stage (p = 0.03). There were no differences between groups on preoperative functional level and QOL measures. Postoperatively, ESS patients reported more tinnitus (p = 0.003) and aural fullness (p = 0.01). There were no differences in posttreatment vertigo class. Secondary treatment was required for 27% of patients in the ESS compared with 3% in the ITG. Posttreatment hearing remained unchanged for the ITG and was overall decreased in the ESS group (p = 0.03). Participants in the ITG reported better postoperative functional levels (p = 0.02) and higher global (p = 0.04), social (p = 0.001), and overall QOL scores (p = 0.03). ITG, compared with ESS, reveals better posttreatment functional levels, and superior global, social, and overall QOL scores. Although no statistical difference in vertigo class, a clinical difference is observed.

Dietary Modification as Adjunct Treatment in Ménière’s Disease

To evaluate ease of use and compliance with dietary modification in the treatment of vertigo in patients with Ménière's disease. Mailed patient retrospective questionnaire and chart review. Tertiary referral neurotologic private practice. 136 patients with Ménière's who returned a mailed questionnaire. Mean age at first clinic visit was 53 years, and at questionnaire was 62 years, with 54.4% female subjects. Median initial hearing was AAO-HNS Stage 1. Most patients also received diuretics and/or other treatments. Reduced sodium and caffeine-free diet. Ratings of diet difficulty, length of use, compliance level and nutritional understanding, and AAO-HNS vertigo class and functional rating before and with nutritional intervention. 46.3% of the respondents received written diet guidelines; only 3.2% were referred for nutritional counseling, and another 7.8% sought counseling independently. 77.8% and 84.7% rated a low sodium and a caffeine-free diet, respectively, as manageable or easy to follow; 77.9% followed the diet for 1 year or greater, but only 10.3% could list 5 "correct" foods to eat and 26% 5 foods to avoid. Those who followed the diet greater than 6 months had larger improvement in number of spells and functional rating and a higher rate of Class A/B vertigo outcome (p ≤ 0.01, p = 0.012, and p = 0.038, respectively). Knowledge of foods to eat and avoid correlated with vertigo class (rho = -0.21, p ≤ 0.029 and rho = -0.26, p ≤ 0.01, respectively); the more foods correctly listed, the better the AAO-HNS class). Nutrition education by referral to a registered dietitian may improve outcomes in the medical treatment of Ménière's disease.

Endolymphatic sac-vein decompression for intractable meniere's disease: long term treatment results

We sought to determine the long-term efficacy of endolymphatic sac-vein decompression surgery on patients with classic Meniere's disease. Using the 1995 American Academy of Otolaryngology-Head and Neck Surgery Committee on Hearing and Equilibrium criteria, starting stage, functional level, vertigo class, and hearing results were addressed. We studied 68 patients with classic Meniere's disease from a tertiary, private otology-neurotology practice. Patient data were gathered by retrospective chart review, questionnaire, and patient interview. All patients underwent endolymphatic sac-vein decompression with an average follow-up period of 55 months. Median functional level before surgery was level 4, improving to level 2 after surgery. Eighty-one percent of patients showed improvement in functional level, 12% remained stable, and 7% declined. Long-term vertigo control was 47% in class A, 25% in class B, 9% in class C, 3% in class D, and 16% in class F. Twenty percent of patients were in hearing stage I Meniere's disease; 31%, stage II; 44%, stage III; and 5%, stage IV. Eighteen percent of patients showed improvement in hearing class, 64% were stable, and 18% declined. Endolymphatic sac-vein decompression surgery is a safe, nondestructive surgical option for Meniere's disease that offers durable control of vertigo and stabilization of hearing for the majority of symptomatic patients. The beneficial long-term outcome of the endolymphatic sac-vein decompression supports its continued use as a first-line treatment option in intractable Meniere's disease.

Endolymphatic sac-vein decompression for intractable Meniere's disease: long term treatment results.

We sought to determine the long-term efficacy of endolymphatic sac-vein decompression surgery on patients with classic Meniere's disease. Using the 1995 American Academy of Otolaryngology-Head and Neck Surgery Committee on Hearing and Equilibrium criteria, starting stage, functional level, vertigo class, and hearing results were addressed. We studied 68 patients with classic Meniere's disease from a tertiary, private otology-neurotology practice. Patient data were gathered by retrospective chart review, questionnaire, and patient interview. All patients underwent endolymphatic sac-vein decompression with an average follow-up period of 55 months. Median functional level before surgery was level 4, improving to level 2 after surgery. Eighty-one percent of patients showed improvement in functional level, 12% remained stable, and 7% declined. Long-term vertigo control was 47% in class A, 25% in class B, 9% in class C, 3% in class D, and 16% in class F. Twenty percent of patients were in hearing stage I Meniere's disease; 31%, stage II; 44%, stage III; and 5%, stage IV. Eighteen percent of patients showed improvement in hearing class, 64% were stable, and 18% declined. Endolymphatic sac-vein decompression surgery is a safe, nondestructive surgical option for Meniere's disease that offers durable control of vertigo and stabilization of hearing for the majority of symptomatic patients. The beneficial long-term outcome of the endolymphatic sac-vein decompression supports its continued use as a first-line treatment option in intractable Meniere's disease.

Long-term follow-up of transtympanic gentamicin for Ménière's syndrome.

Recent studies have shown that transtympanic gentamicin for Ménière's syndrome is effective. Current treatment protocols vary. One concept has been to perform a chemical ablation; the other has been to perform a chemical alteration. Ablation requires multiple injections and is effective in controlling the vertigo, but it is associated with a significant incidence of hearing loss. Chemical alteration uses a minimal dose to reduce vestibular function without affecting cochlear function. Prospective. Tertiary medical center. Patients had classic unilateral Ménière's syndrome that was unresponsive to medical therapy. A single injection of gentamicin is given, and the patient is seen 1 month after injection. If indicated, the patient receives another injection and is reevaluated 1 month later. Control of vertigo and maintenance of hearing using the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) guidelines (1995). Fifty-six patients have documented follow-up for 2 years or more, and 21 have 4 years or more of follow-up. This article presents the 4-year results as outlined by the AAO-HNS guidelines. Vertigo classes A and B were seen in 82% of patients. The patients followed 2 to 4 years had 86% vertigo class A and B results. Those followed 4 years or more show 76% with a vertigo class A or B result. In this study there has been minimal cochlear loss. There was vestibular change clinically, which was documented by electronystagmography. It appears that a single transtympanic gentamicin injection is effective in controlling the vertigo of Ménière's syndrome. Cochlear impact has been minimal. It is most useful for those patients who have failed medical management and are severely affected but not totally incapacitated by the disease.